» » The 2007-2012 Outlook for Biological Veterinary Vaccines, Bacterins, Toxoids, Other Antigens, and Other Biological Products in India

Download The 2007-2012 Outlook for Biological Veterinary Vaccines, Bacterins, Toxoids, Other Antigens, and Other Biological Products in India fb2

by Philip M. Parker

  • ISBN: 0497491524
  • Category: Money & Business
  • Author: Philip M. Parker
  • Subcategory: Economics
  • Other formats: rtf lrf lit doc
  • Language: English
  • Publisher: ICON Group International, Inc (September 28, 2006)
  • Pages: 325 pages
  • FB2 size: 1487 kb
  • EPUB size: 1383 kb
  • Rating: 4.9
  • Votes: 643
Download The 2007-2012 Outlook for Biological Veterinary Vaccines, Bacterins, Toxoids, Other Antigens, and Other Biological Products in India fb2

Published September 28, 2006 by ICON Group International, In. .

Published September 28, 2006 by ICON Group International, In.

Categories Prices Producer Price Indexes (PPI) Commodity Based Chemicals and Allied Products

Graph and download economic data for Producer Price Index by Commodity for Chemicals and Allied Products: Biological Veterinary Vaccines, Bacterins, Toxoids, Other Antigens, and Other Biologics (WPU06371702) from Jun 2009 to Jul 2016 about veterinary, chemicals, commodities, PPI, inflation, price index, price, indexes, and US. Categories Prices Producer Price Indexes (PPI) Commodity Based Chemicals and Allied Products. Producer Price Index by Commodity for Chemicals and Allied Products: Biological Veterinary Vaccines, Bacterins, Toxoids, Other Antigens, and Other Biologics (WPU06371702).

Author : Philip M. Parker. Publisher : ICON Group International, Inc. Book Price. R. 9,522 on (FREE Delivery).

Other attenuated viral vaccines in use include the veterinary strain of rabies (known as.Biological products offer the hope of treatments for many debilitating diseases.

Other attenuated viral vaccines in use include the veterinary strain of rabies (known as the ERA strain), developed at Connaught but now part of SANOFI PASTEUR LIMITED, and the measles and rubella strains currently being widely used. When injected, toxoids induce the formation of antibodies against the original toxin. Some other bacterial vaccines produced include typhus, typhoid, cholera, haemophilus, influenzae type B, pneumococcus, meningococcus and bacille Calmette-Guérin (BCG, used for the prevention of tuberculosis).

Inputs and outputs for biological product (except diagnostic) manufacturing.

Biological products, except diagnostic, blood and blood derivatives, other blood and blood derivatives or fractions, except those used for passive immunization. Inputs and outputs for biological product (except diagnostic) manufacturing. Economic Sector or Industry Providing Inputs.

We characterized five different vaccine candidates and a commercial vaccine in terms of safety, immunogenicity and using a systems vaccinology approach, with the aim to select novel vaccine candidates against Mycoplasma hyopneumoniae.

over veterinary vaccines for other purposes (. 9 CFR 102, Licenses for biological products

It is important to note that the USDA has regulatory authority only over those veterinary vaccines specifically for the prevention and treatment of animal diseases; the Food and Drug Administration (FDA) has regulatory jurisdiction over veterinary vaccines for other purposes (. vaccines targeting some hormones or pain receptors). 9 CFR 102, Licenses for biological products. gov/animal health/vet biologics/vb cfr.

SIC Code 2836 - Biological Products, except Diagnostic Substances

SIC Code 2836 - Biological Products, except Diagnostic Substances. Description Hierarchy Industry Examples Cross-References Companies Extended SIC Codes Related Code Systems. Establishments primarily engaged in the production of bacterial and virus vaccines, toxoids, and analogous products (such as allergenic extracts), serums, plasmas, and other blood derivatives for human or veterinary use, other than in vitro and in vivo diagnostic substances. Included in this industry are establishments primarily engaged in the production of microbiological products for other uses.

Biological vaccines products are most popular in Domestic Market, South America, and Southeast Asia. You can ensure product safety by selecting from certified suppliers, including 256 with Other, 190 with ISO9001, and 144 with ISO14001 certification

Biological vaccines products are most popular in Domestic Market, South America, and Southeast Asia. You can ensure product safety by selecting from certified suppliers, including 256 with Other, 190 with ISO9001, and 144 with ISO14001 certification.

To date, the most promising antigens in the development of a subunit vaccine are the Lig proteins.

4 USDA APHIS Biological Products, Organisms and Vectors, and Plant Pathogens Permitting Program: Import and Interstate Transfer of Agricultural Pathogens. To date, the most promising antigens in the development of a subunit vaccine are the Lig proteins. These proteins are exclusively expressed during host infection, and they are involved in immune evasion mechanisms and also in Leptospira adhesion to host cells. Different fragments of the LigA protein were able to confer 100% protection in a hamster model of leptospirosis.

This study covers the latent demand outlook for biological veterinary vaccines, bacterins, toxoids, other antigens, and other biological products across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 5,000 cities in India. For each city in question, the percent share the city is of it’s state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for biological veterinary vaccines, bacterins, toxoids, other antigens, and other biological products. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

Related to The 2007-2012 Outlook for Biological Veterinary Vaccines, Bacterins, Toxoids, Other Antigens, and Other Biological Products in India fb2 books: